Parathyroid hormone is not involved in prostate growth in patients with benign prostatic hyperplasia.
A recent population-based study reported that serum calcium and parathyroid hormone stimulate prostate growth. We evaluated whether serum PTH, vitamin D, and calcium levels correlate with prostate size, PSA levels, and obesity in Korean patients with histologically proven BPH. Patients with histopathologically proven BPH who underwent transurethral resection of the prostate were enrolled (n = 289). Patients with PSA levels of ≥3 ng/ml underwent multicore transrectal prostate biopsy before TURP to rule out prostate cancer. Patients with serum creatinine levels >1.4 mg/dl, PSA levels >20 ng/ml, and/or PTH levels <10 pg/ml were excluded. Correlations between serum parameters and clinical data were determined. After adjustment for potential confounders, including age and body mass index, multiple linear regression served to compute associations. The mean age, serum PSA level, PTH level, and prostate size were 68.13 ± 7.15 years, 4.10 ± 3.88 ng/ml, 24.33 ± 12.52 pg/ml, and 44.27 ± 24.15 g, respectively. Prostate size correlated positively with age (r = 0.209, P < 0.001) and PSA levels (r = 0.481, P < 0.001), and PSA levels correlated positively with age (r = 0.226, P < 0.001) and prostate size (r = 0.481, P < 0.001), but neither variable correlated with PTH, vitamin D, calcium levels, or BMI. Upon multiple adjusted linear regression analysis, prostate size correlated with BMI and serum PSA (both P < 0.001), and serum PSA levels correlated with BMI and prostate size (P = 0.007, P < 0.001, respectively), but neither variable correlated with PTH, vitamin D, or serum calcium levels. In Korean patients with histopathologically proven BPH, high PTH, vitamin D, and calcium levels do not stimulate prostate growth.